

SymBio Pharmaceuticals

Treakisym approvals should lead to sales uplift

Product approval

Pharma & biotech

6 January 2017

Price **¥254**

Market cap **¥11,638m**

¥118/\$

Cash (¥m) at 30 September 2016 6,078

Shares in issue 45.82m

Free float 77%

Code 4582

Primary exchange Japan

Secondary exchange OTC US

Share price performance



Business description

SymBio Pharmaceuticals is a Japanese specialty pharma company with a focus on oncology, haematology and pain management. Treakisym was in-licensed from Astellas in 2005. Rigosertib was in-licensed from Onconova and IONSYS was in-licensed from The Medicines Company.

Analysts

Dr Philippa Gardner +44 (0)20 3077 5727

Maxim Jacobs +1 646 653 7027

healthcare@edisongroup.com

[Edison profile page](#)

SymBio Pharmaceuticals is a research client of Edison Investment Research Limited

SymBio recently obtained approvals for Treakisym in Japan in the additional indications of first-line low grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL). This follows on from the Aug 2016 approval in chronic lymphocytic leukaemia. We believe these additional indications could nearly double current Treakisym sales (on track for c \$40m in 2016) via partner Eisai, which to date have been mostly in relapsed or refractory (r/r) low grade NHL/MCL. These approvals represent an important step in SymBio's strategy to maximise Treakisym's potential.

Year end	Revenue (¥m)	PBT* (¥m)	EPS* (¥)	DPS (¥)	P/E (x)	Yield (%)
12/14	1,955	(1,116)	(36.39)	0.0	N/A	N/A
12/15	1,933	(2,640)	(81.61)	0.0	N/A	N/A
12/16e	1,951	(2,733)	(84.51)	0.0	N/A	N/A
12/17e	2,290	(3,326)	(102.80)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles. Note: our financial forecasts will be updated post the FY16 financial report during Q117.

To date, Treakisym sales in Japan have largely been in the c 4,700 patients with r/r low grade NHL/MCL, with around a 60% share, according to SymBio. With c 7,100 first-line low grade NHL/MCL patients and more treatment cycles per patient on average, this indication could materially expand Treakisym's potential. We expect a formal launch by partner Eisai during Q117. We estimate that SymBio earns an average net margin of 10-12% on top-line Treakisym sales. We believe the main risk to future Treakisym sales will be drug pricing dynamics in Japan, with an increasing focus on cancer. To date, Treakisym pricing has been stable and our forecasts assume continued stable pricing. The next price review will be in 2018.

In November 2016 SymBio enrolled the first patient in the Phase III trial of IONSYS (SyB P-1501) for the management of postoperative pain; this was in line with expected timelines and SymBio continues to target launch in 2019. Rigosertib IV, with partner Onconova, continues in the global Phase III INSPIRE trial in second-line higher-risk myelodysplastic syndromes (HR-MDS), to which SymBio has committed to contribute >20 patients; SymBio enrolled its first patient in July 2016. Provision of oral rigosertib by Onconova for the Phase I trial in Japan in first-line HR-MDS has been delayed, slowing trial progression. As well as incorporating its US subsidiary in May 2016, SymBio Pharma USA Inc, SymBio continues to evaluate numerous drug candidates to complement and build its pipeline.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt and Sydney. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by SymBio Pharmaceuticals and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE data is permitted without FTSE's express written consent.